Roivant Sciences Ltd. (ROIV) · Insider trading
What Roivant Sciences's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$877.68M
12 insiders, 17% under a plan
Net, 12 months
−$877.68M
bought less sold
Latest filing
2026-10-05
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Venker EricPresident & Immunovant CEO | – | $161.89M | 45 | 2026-09-30 | 1,599,154 |
| Ramaswamy Vivek10% owner | – | $160.01M | 15 | 2025-12-15 | 34,132,463 |
| Manchester Keith SDirector | – | $154.47M | 20 | 2026-06-30 | – |
| Qvt Financial LPOther | – | $147.38M | 19 | 2026-06-30 | – |
| Gold Daniel AllenDirector | – | $147.38M | 19 | 2026-06-30 | – |
| Sukhatme MayukhDirector, President & CIO | – | $124.75M | 17 | 2026-08-21 | 18,630,739 |
| Torti FrankPresident and Vant Chair | – | $82.04M | 3 | 2026-02-23 | 13,736,547 |
| Gline MatthewDirector, CEO | $49,957 | $46.17M | 5 | 2026-04-16 | 16,736,116 |
| Pulik RichardCFO | – | $9.12M | 2 | 2025-12-23 | 386,144 |
| Fitzgerald MeghanDirector | – | $3.27M | 5 | 2026-09-15 | 36,508 |
| Epperly Melissa B,Director | – | $2.65M | 7 | 2026-10-01 | 15,854 |
| Kumar RakhiChief Accounting Officer | – | $2.37M | 1 | 2025-02-13 | 163,264 |
| Humes JenniferChief Accounting Officer | – | $384,073 | 1 | 2026-04-08 | 84,191 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Epperly Melissa B,Director | Saleplan | 16,850 | 36.08 | $607,948 | 15,854 | Form 4 |
| 2026-10-01 | Epperly Melissa B,Director | Saleplan | 900 | 36.57 | $32,913 | 14,954 | Form 4 |
| 2026-09-30 | Venker EricPresident & Immunovant CEO | Saleplan | 200,000 | 36.62 | $7.32M | 1,599,154 | Form 4 |
| 2026-09-15 | Fitzgerald MeghanDirector | Saleplan | 4,712 | 39.68 | $186,972 | 36,508 | Form 4 |
| 2026-09-15 | Fitzgerald MeghanDirector | Saleplan | 400 | 40.45 | $16,180 | 36,108 | Form 4 |
| 2026-09-15 | Epperly Melissa B,Director | Saleplan | 4,338 | 39.65 | $172,002 | 10,500 | Form 4 |
| 2026-09-15 | Epperly Melissa B,Director | Saleplan | 600 | 40.38 | $24,228 | 9,900 | Form 4 |
| 2026-09-08 | Fitzgerald MeghanDirector | Saleplan | 20,000 | 39.90 | $798,000 | 42,963 | Form 4 |
| 2026-08-28 | Venker EricPresident & Immunovant CEO | Saleplan | 166,182 | 35.63 | $5.92M | 1,632,972 | Form 4 |
| 2026-08-28 | Venker EricPresident & Immunovant CEO | Saleplan | 33,818 | 36.44 | $1.23M | 1,599,154 | Form 4 |
| 2026-08-21 | Sukhatme MayukhDirector, President & CIO | Sale | 144,756 | 36.48 | $5.28M | 18,630,739 | Form 4 |
| 2026-08-20 | Sukhatme MayukhDirector, President & CIO | Sale | 17,519 | 37.30 | $653,459 | 18,630,739 | Form 4 |
| 2026-08-19 | Sukhatme MayukhDirector, President & CIO | Sale | 172,899 | 37.17 | $6.43M | 18,630,739 | Form 4 |
| 2026-08-18 | Sukhatme MayukhDirector, President & CIO | Sale | 105,141 | 36.59 | $3.85M | 18,630,739 | Form 4 |
| 2026-08-18 | Sukhatme MayukhDirector, President & CIO | Sale | 31,801 | 37.18 | $1.18M | 18,630,739 | Form 4 |
| 2026-08-17 | Sukhatme MayukhDirector, President & CIO | Sale | 284,707 | 36.25 | $10.32M | 18,630,739 | Form 4 |
| 2026-08-14 | Sukhatme MayukhDirector, President & CIO | Sale | 243,177 | 36.23 | $8.81M | 18,630,739 | Form 4 |
| 2026-07-27 | Venker EricPresident & Immunovant CEO | Saleplan | 200,000 | 34.95 | $6.99M | 1,613,063 | Form 4 |
| 2026-06-30 | Fitzgerald MeghanDirector | Saleplan | 10,000 | 34.90 | $349,000 | 42,963 | Form 4 |
| 2026-06-30 | Qvt Financial LPOther | Saleindirect | 12,380 | 35.28 | $436,766 | 13,689,166 | Form 4 |
| 2026-06-30 | Gold Daniel AllenDirector | Saleindirect | 12,380 | 35.28 | $436,766 | 13,689,166 | Form 4 |
| 2026-06-30 | Manchester Keith SDirector | Saleindirect | 12,380 | 35.28 | $436,766 | 13,689,166 | Form 4 |
| 2026-06-30 | Manchester Keith SDirector | Sale | 200,000 | 35.45 | $7.09M | 1,748,403 | Form 4 |
| 2026-06-29 | Epperly Melissa B,Director | Saleplan | 15,002 | 34.32 | $514,869 | 19,222 | Form 4 |
| 2026-06-29 | Epperly Melissa B,Director | Saleplan | 2,748 | 34.71 | $95,383 | 16,474 | Form 4 |
| 2026-06-29 | Qvt Financial LPOther | Saleindirect | 200,000 | 34.44 | $6.89M | 14,301,546 | Form 4 |
| 2026-06-29 | Qvt Financial LPOther | Saleindirect | 600,000 | 34.59 | $20.75M | 13,701,546 | Form 4 |
| 2026-06-29 | Gold Daniel AllenDirector | Saleindirect | 200,000 | 34.44 | $6.89M | 14,301,546 | Form 4 |
| 2026-06-29 | Gold Daniel AllenDirector | Saleindirect | 600,000 | 34.59 | $20.75M | 13,701,546 | Form 4 |
| 2026-06-29 | Manchester Keith SDirector | Saleindirect | 200,000 | 34.44 | $6.89M | 14,301,546 | Form 4 |
| 2026-06-29 | Manchester Keith SDirector | Saleindirect | 600,000 | 34.59 | $20.75M | 13,701,546 | Form 4 |
| 2026-06-26 | Qvt Financial LPOther | Saleindirect | 300,783 | 33.92 | $10.20M | 14,826,546 | Form 4 |
| 2026-06-26 | Qvt Financial LPOther | Saleindirect | 325,000 | 34.07 | $11.07M | 14,501,546 | Form 4 |
| 2026-06-26 | Gold Daniel AllenDirector | Saleindirect | 300,783 | 33.92 | $10.20M | 14,826,546 | Form 4 |
| 2026-06-26 | Gold Daniel AllenDirector | Saleindirect | 325,000 | 34.07 | $11.07M | 14,501,546 | Form 4 |
| 2026-06-26 | Manchester Keith SDirector | Saleindirect | 300,783 | 33.92 | $10.20M | 14,826,546 | Form 4 |
| 2026-06-26 | Manchester Keith SDirector | Saleindirect | 325,000 | 34.07 | $11.07M | 14,501,546 | Form 4 |
| 2026-06-26 | Sukhatme MayukhDirector, President & CIO | Sale | 500,000 | 34.08 | $17.04M | 18,677,617 | Form 4 |
| 2026-06-25 | Sukhatme MayukhDirector, President & CIO | Sale | 500,000 | 34.13 | $17.07M | 18,677,617 | Form 4 |
| 2026-06-24 | Venker EricPresident & Immunovant CEO | Saleplan | 153,766 | 33.05 | $5.08M | 1,659,297 | Form 4 |
119 more
| 2026-06-24 | Venker EricPresident & Immunovant CEO | Saleplan | 46,234 | 33.51 | $1.55M | 1,613,063 | Form 4 |
| 2026-05-22 | Venker EricPresident & Immunovant CEO | Saleplan | 200,000 | 30.27 | $6.05M | 1,613,063 | Form 4 |
| 2026-04-20 | Venker EricPresident & Immunovant CEO | Saleplan | 200,000 | 29.59 | $5.92M | 1,647,546 | Form 4 |
| 2026-04-16 | Gline MatthewDirector, CEO | Sale | 289,774 | 29.16 | $8.45M | 16,736,116 | Form 4 |
| 2026-04-08 | Humes JenniferChief Accounting Officer | Sale | 13,538 | 28.37 | $384,073 | 84,191 | Form 4 |
| 2026-03-26 | Fitzgerald MeghanDirector | Sale | 70,000 | 27.45 | $1.92M | 42,963 | Form 4 |
| 2026-03-17 | Venker EricPresident & Immunovant CEO | Saleplan | 200,000 | 28.24 | $5.65M | 1,647,546 | Form 4 |
| 2026-03-16 | Epperly Melissa B,Director | Sale | 41,861 | 28.68 | $1.20M | 15,804 | Form 4 |
| 2026-02-23 | Torti FrankPresident and Vant Chair | Saleplan | 587,390 | 27.51 | $16.16M | 13,736,547 | Form 4 |
| 2026-02-20 | Torti FrankPresident and Vant Chair | Saleplan | 1,012,610 | 27.15 | $27.49M | 13,736,547 | Form 4 |
| 2026-02-19 | Torti FrankPresident and Vant Chair | Saleplan | 1,400,000 | 27.42 | $38.39M | 13,736,547 | Form 4 |
| 2026-02-13 | Venker EricPresident & Immunovant CEO | Saleplan | 200,000 | 26.49 | $5.30M | 1,654,597 | Form 4 |
| 2026-02-13 | Qvt Financial LPOther | Saleindirect | 150,784 | 26.49 | $3.99M | 15,352,329 | Form 4 |
| 2026-02-13 | Qvt Financial LPOther | Saleindirect | 225,000 | 26.50 | $5.96M | 15,127,329 | Form 4 |
| 2026-02-13 | Gold Daniel AllenDirector | Saleindirect | 150,784 | 26.49 | $3.99M | 15,352,329 | Form 4 |
| 2026-02-13 | Gold Daniel AllenDirector | Saleindirect | 225,000 | 26.50 | $5.96M | 15,127,329 | Form 4 |
| 2026-02-13 | Manchester Keith SDirector | Saleindirect | 150,784 | 26.49 | $3.99M | 15,352,329 | Form 4 |
| 2026-02-13 | Manchester Keith SDirector | Saleindirect | 225,000 | 26.50 | $5.96M | 15,127,329 | Form 4 |
| 2026-02-12 | Qvt Financial LPOther | Saleindirect | 150,000 | 26.72 | $4.01M | 15,778,113 | Form 4 |
| 2026-02-12 | Qvt Financial LPOther | Saleindirect | 275,000 | 26.76 | $7.36M | 15,503,113 | Form 4 |
| 2026-02-12 | Gold Daniel AllenDirector | Saleindirect | 150,000 | 26.72 | $4.01M | 15,778,113 | Form 4 |
| 2026-02-12 | Gold Daniel AllenDirector | Saleindirect | 275,000 | 26.76 | $7.36M | 15,503,113 | Form 4 |
| 2026-02-12 | Manchester Keith SDirector | Saleindirect | 150,000 | 26.72 | $4.01M | 15,778,113 | Form 4 |
| 2026-02-12 | Manchester Keith SDirector | Saleindirect | 275,000 | 26.76 | $7.36M | 15,503,113 | Form 4 |
| 2026-02-11 | Qvt Financial LPOther | Saleindirect | 425,000 | 26.67 | $11.33M | 15,928,113 | Form 4 |
| 2026-02-11 | Gold Daniel AllenDirector | Saleindirect | 425,000 | 26.67 | $11.33M | 15,928,113 | Form 4 |
| 2026-02-11 | Manchester Keith SDirector | Saleindirect | 425,000 | 26.67 | $11.33M | 15,928,113 | Form 4 |
| 2026-02-09 | Sukhatme MayukhDirector, President & CIO | Sale | 339,441 | 26.47 | $8.99M | 19,148,664 | Form 4 |
| 2026-01-12 | Venker EricPresident & Immunovant CEO | Saleplan | 200,000 | 21.92 | $4.38M | 1,654,597 | Form 4 |
| 2025-12-31 | Sukhatme MayukhDirector, President & CIO | Sale | 1,018,995 | 21.71 | $22.12M | 20,267,429 | Form 4 |
| 2025-12-29 | Sukhatme MayukhDirector, President & CIO | Sale | 311,873 | 21.74 | $6.78M | 19,273,032 | Form 4 |
| 2025-12-24 | Venker EricPresident & Immunovant CEO | Sale | 75,000 | 22.53 | $1.69M | 1,654,597 | Form 4 |
| 2025-12-23 | Venker EricPresident & Immunovant CEO | Sale | 200,000 | 22.45 | $4.49M | 1,611,749 | Form 4 |
| 2025-12-23 | Pulik RichardCFO | Sale | 260,000 | 22.45 | $5.84M | 386,144 | Form 4 |
| 2025-12-23 | Pulik RichardCFO | Sale | 146,731 | 22.39 | $3.29M | 239,413 | Form 4 |
| 2025-12-17 | Sukhatme MayukhDirector, President & CIO | Sale | 26,831 | 23.09 | $619,528 | 18,869,229 | Form 4 |
| 2025-12-17 | Qvt Financial LPOther | Saleindirect | 432,718 | 23.05 | $9.97M | 16,697,727 | Form 4 |
| 2025-12-17 | Qvt Financial LPOther | Saleindirect | 155,076 | 23.02 | $3.57M | 16,542,651 | Form 4 |
| 2025-12-17 | Qvt Financial LPOther | Saleindirect | 189,538 | 23.17 | $4.39M | 16,353,113 | Form 4 |
| 2025-12-17 | Manchester Keith SDirector | Saleindirect | 432,718 | 23.05 | $9.97M | 16,697,727 | Form 4 |
| 2025-12-17 | Manchester Keith SDirector | Saleindirect | 155,076 | 23.02 | $3.57M | 16,542,651 | Form 4 |
| 2025-12-17 | Manchester Keith SDirector | Saleindirect | 189,538 | 23.17 | $4.39M | 16,353,113 | Form 4 |
| 2025-12-17 | Gold Daniel AllenDirector | Saleindirect | 432,718 | 23.05 | $9.97M | 16,697,727 | Form 4 |
| 2025-12-17 | Gold Daniel AllenDirector | Saleindirect | 155,076 | 23.02 | $3.57M | 16,542,651 | Form 4 |
| 2025-12-17 | Gold Daniel AllenDirector | Saleindirect | 189,538 | 23.17 | $4.39M | 16,353,113 | Form 4 |
| 2025-12-16 | Qvt Financial LPOther | Saleindirect | 275,000 | 22.93 | $6.31M | 17,772,727 | Form 4 |
| 2025-12-16 | Qvt Financial LPOther | Saleindirect | 642,282 | 23.08 | $14.82M | 17,130,445 | Form 4 |
| 2025-12-16 | Manchester Keith SDirector | Saleindirect | 275,000 | 22.93 | $6.31M | 17,772,727 | Form 4 |
| 2025-12-16 | Manchester Keith SDirector | Saleindirect | 642,282 | 23.08 | $14.82M | 17,130,445 | Form 4 |
| 2025-12-16 | Gold Daniel AllenDirector | Saleindirect | 275,000 | 22.93 | $6.31M | 17,772,727 | Form 4 |
| 2025-12-16 | Gold Daniel AllenDirector | Saleindirect | 642,282 | 23.08 | $14.82M | 17,130,445 | Form 4 |
| 2025-12-15 | Gline MatthewDirector, CEO | Sale | 230,357 | 21.68 | $4.99M | 17,290,820 | Form 4 |
| 2025-12-15 | Gline MatthewDirector, CEO | Sale | 566,116 | 21.68 | $12.27M | 18,084,676 | Form 4 |
| 2025-12-15 | Gline MatthewDirector, CEO | Sale | 943,527 | 21.68 | $20.46M | 18,616,406 | Form 4 |
| 2025-12-15 | Ramaswamy Vivek10% owner | Sale | 353,745 | 22.05 | $7.80M | 34,132,463 | Form 4 |
| 2025-12-12 | Ramaswamy Vivek10% owner | Sale | 1,975,858 | 21.96 | $43.39M | 36,350,621 | Form 4 |
| 2025-12-11 | Ramaswamy Vivek10% owner | Sale | 774,142 | 21.64 | $16.75M | 34,749,305 | Form 4 |
| 2025-12-09 | Venker EricPresident & Immunovant CEO | Saleplan | 200,000 | 20.85 | $4.17M | 1,497,908 | Form 4 |
| 2025-11-19 | Qvt Financial LPOther | Saleindirect | 850,000 | 20.25 | $17.21M | 18,497,727 | Form 4 |
| 2025-11-19 | Qvt Financial LPOther | Saleindirect | 150,000 | 20.20 | $3.03M | 18,347,727 | Form 4 |
| 2025-11-19 | Qvt Financial LPOther | Saleindirect | 125,000 | 20.16 | $2.52M | 18,222,727 | Form 4 |
| 2025-11-19 | Qvt Financial LPOther | Saleindirect | 175,000 | 20.24 | $3.54M | 18,047,727 | Form 4 |
| 2025-11-19 | Gold Daniel AllenDirector | Saleindirect | 850,000 | 20.25 | $17.21M | 18,497,727 | Form 4 |
| 2025-11-19 | Gold Daniel AllenDirector | Saleindirect | 150,000 | 20.20 | $3.03M | 18,347,727 | Form 4 |
| 2025-11-19 | Gold Daniel AllenDirector | Saleindirect | 125,000 | 20.16 | $2.52M | 18,222,727 | Form 4 |
| 2025-11-19 | Gold Daniel AllenDirector | Saleindirect | 175,000 | 20.24 | $3.54M | 18,047,727 | Form 4 |
| 2025-11-19 | Manchester Keith SDirector | Saleindirect | 850,000 | 20.25 | $17.21M | 18,497,727 | Form 4 |
| 2025-11-19 | Manchester Keith SDirector | Saleindirect | 150,000 | 20.20 | $3.03M | 18,347,727 | Form 4 |
| 2025-11-19 | Manchester Keith SDirector | Saleindirect | 125,000 | 20.16 | $2.52M | 18,222,727 | Form 4 |
| 2025-11-19 | Manchester Keith SDirector | Saleindirect | 175,000 | 20.24 | $3.54M | 18,047,727 | Form 4 |
| 2025-11-17 | Ramaswamy Vivek10% owner | Sale | 539,650 | 20.51 | $11.07M | 33,653,756 | Form 4 |
| 2025-11-14 | Ramaswamy Vivek10% owner | Sale | 1,027,670 | 20.33 | $20.89M | 34,193,406 | Form 4 |
| 2025-11-13 | Ramaswamy Vivek10% owner | Sale | 287,283 | 20.81 | $5.98M | 35,221,076 | Form 4 |
| 2025-11-07 | Venker EricPresident & Immunovant CEO | Saleplan | 200,000 | 20.22 | $4.04M | 1,504,959 | Form 4 |
| 2025-10-17 | Venker EricPresident & Immunovant CEO | Saleplan | 118,418 | 17.06 | $2.02M | 1,504,959 | Form 4 |
| 2025-10-16 | Venker EricPresident & Immunovant CEO | Saleplan | 318,282 | 17.05 | $5.43M | 1,504,959 | Form 4 |
| 2025-10-15 | Venker EricPresident & Immunovant CEO | Saleplan | 414,683 | 16.93 | $7.02M | 1,504,959 | Form 4 |
| 2025-10-13 | Venker EricPresident & Immunovant CEO | Saleplan | 20,727 | 16.25 | $336,814 | 1,504,959 | Form 4 |
| 2025-10-09 | Venker EricPresident & Immunovant CEO | Saleplan | 104,940 | 16.30 | $1.71M | 1,504,959 | Form 4 |
| 2025-10-08 | Venker EricPresident & Immunovant CEO | Saleplan | 138,602 | 16.20 | $2.25M | 1,504,959 | Form 4 |
| 2025-10-07 | Venker EricPresident & Immunovant CEO | Saleplan | 355,161 | 16.15 | $5.74M | 1,504,959 | Form 4 |
| 2025-10-06 | Venker EricPresident & Immunovant CEO | Saleplan | 171,396 | 16.34 | $2.80M | 1,504,959 | Form 4 |
| 2025-09-23 | Venker EricPresident & Immunovant CEO | Saleplan | 611,000 | 14.83 | $9.06M | 1,504,959 | Form 4 |
| 2025-09-22 | Venker EricPresident & Immunovant CEO | Saleplan | 316,182 | 14.99 | $4.74M | 2,215,959 | Form 4 |
| 2025-09-22 | Venker EricPresident & Immunovant CEO | Saleplan | 100,000 | 15.01 | $1.50M | 2,115,959 | Form 4 |
| 2025-09-19 | Venker EricPresident & Immunovant CEO | Saleplan | 683,818 | 14.95 | $10.22M | 1,969,767 | Form 4 |
| 2025-09-18 | Gline MatthewDirector, CEO | Buy | 3,315 | 15.07 | $49,957 | 17,287,081 | Form 4 |
| 2025-09-05 | Ramaswamy Vivek10% owner | Sale | 385,816 | 12.96 | $5.00M | 35,508,359 | Form 4 |
| 2025-09-04 | Ramaswamy Vivek10% owner | Sale | 194,933 | 12.92 | $2.52M | 35,894,175 | Form 4 |
| 2025-09-03 | Ramaswamy Vivek10% owner | Sale | 1,195,000 | 12.50 | $14.94M | 36,089,108 | Form 4 |
| 2025-08-20 | Venker EricPresident & Immunovant CEO | Saleplan | 100,000 | 11.72 | $1.17M | 1,653,585 | Form 4 |
| 2025-07-21 | Venker EricPresident & Immunovant CEO | Saleplan | 100,000 | 11.52 | $1.15M | 1,462,223 | Form 4 |
| 2025-06-20 | Venker EricPresident & COO | Saleplan | 100,000 | 11.45 | $1.15M | 1,462,223 | Form 4 |
| 2025-06-20 | Ramaswamy Vivek10% owner | Sale | 577,007 | 11.46 | $6.61M | 37,284,108 | Form 4 |
| 2025-06-18 | Ramaswamy Vivek10% owner | Sale | 565,266 | 11.45 | $6.47M | 37,861,115 | Form 4 |
| 2025-06-06 | Ramaswamy Vivek10% owner | Sale | 200,800 | 11.19 | $2.25M | 38,426,381 | Form 4 |
| 2025-06-04 | Ramaswamy Vivek10% owner | Sale | 547,430 | 11.34 | $6.21M | 38,627,181 | Form 4 |
| 2025-06-03 | Venker EricPresident & COO | Sale | 566,278 | 11.22 | $6.35M | 1,462,223 | Form 4 |
| 2025-06-02 | Venker EricPresident & COO | Sale | 433,722 | 11.07 | $4.80M | 1,243,475 | Form 4 |
| 2025-05-20 | Venker EricPresident & COO | Saleplan | 100,000 | 10.95 | $1.09M | 1,077,197 | Form 4 |
| 2025-05-07 | Ramaswamy Vivek10% owner | Sale | 625,000 | 11.18 | $6.99M | 39,174,611 | Form 4 |
| 2025-05-06 | Ramaswamy Vivek10% owner | Sale | 273,959 | 11.47 | $3.14M | 39,799,611 | Form 4 |
| 2025-04-21 | Venker EricPresident & COO | Saleplan | 100,000 | 10.22 | $1.02M | 1,116,345 | Form 4 |
| 2025-03-24 | Venker EricPresident & COO | Saleplan | 434,478 | 10.82 | $4.70M | 1,127,290 | Form 4 |
| 2025-03-20 | Venker EricPresident & COO | Saleplan | 315,522 | 11.06 | $3.49M | 959,457 | Form 4 |
| 2025-02-20 | Venker EricPresident & COO | Sale | 100,000 | 10.65 | $1.06M | 896,869 | Form 4 |
| 2025-02-13 | Kumar RakhiChief Accounting Officer | Sale | 227,500 | 10.43 | $2.37M | 163,264 | Form 4 |
| 2025-02-13 | Venker EricPresident & COO | Sale | 218,041 | 10.42 | $2.27M | 896,869 | Form 4 |
| 2025-02-12 | Venker EricPresident & COO | Sale | 217,384 | 10.53 | $2.29M | 732,294 | Form 4 |
| 2025-01-21 | Venker EricPresident & COO | Saleplan | 100,000 | 11.28 | $1.13M | 732,294 | Form 4 |
| 2024-12-30 | Venker EricPresident & COO | Sale | 177,704 | 11.54 | $2.05M | 740,976 | Form 4 |
| 2024-12-27 | Venker EricPresident & COO | Sale | 176,900 | 11.82 | $2.09M | 668,680 | Form 4 |
| 2024-12-26 | Sukhatme MayukhDirector, Pres&Chief Investment Officer | Sale | 689,495 | 12.01 | $8.28M | 18,836,547 | Form 4 |
| 2024-12-24 | Sukhatme MayukhDirector, Pres&Chief Investment Officer | Sale | 185,946 | 12.00 | $2.23M | 18,836,547 | Form 4 |
| 2024-12-23 | Sukhatme MayukhDirector, Pres&Chief Investment Officer | Sale | 10,796 | 12.00 | $129,552 | 18,836,547 | Form 4 |
| 2024-12-20 | Venker EricPresident & COO | Saleplan | 100,000 | 11.49 | $1.15M | 595,580 | Form 4 |
| 2024-12-18 | Sukhatme MayukhDirector, Pres&Chief Investment Officer | Sale | 412,584 | 12.05 | $4.97M | 18,836,547 | Form 4 |
| 2024-11-20 | Venker EricPresident & COO | Saleplan | 100,000 | 11.32 | $1.13M | 606,525 | Form 4 |
| 2024-10-21 | Venker EricPresident & COO | Sale | 100,000 | 11.65 | $1.17M | 617,470 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
85 × shares withheld for tax82 × option exercise44 × grant or award33 × other3 × gift
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-10-01 | Epperly Melissa B,Director | Option exercise M | +17,750 | 4.46 | 32,704 | Form 4 |
| 2026-09-30 | Torti FrankPresident and Vant Chair | Shares withheld for tax F | +40,309 | 36.57 | 13,495,893 | Form 4 |
| 2026-09-30 | Gline MatthewDirector, CEO | Shares withheld for tax F | −76,171 | 36.57 | 16,583,774 | Form 4 |
| 2026-09-30 | Venker EricPresident & Immunovant CEO | Option exercise M | +200,000 | 3.85 | 1,799,154 | Form 4 |
| 2026-09-30 | Sukhatme MayukhDirector, President & CIO | Shares withheld for tax F | −46,879 | 36.57 | 18,583,860 | Form 4 |
| 2026-09-20 | Humes JenniferChief Accounting Officer | Shares withheld for tax F | −3,880 | 39.77 | 106,419 | Form 4 |
| 2026-09-20 | Pulik RichardCFO | Shares withheld for tax F | −2,129 | 39.77 | 269,681 | Form 4 |
| 2026-09-16 | Manchester Keith SDirector | Grant or award A | +5,054 | – | 1,753,457 | Form 4 |
| 2026-09-16 | Momtazee James CDirector | Grant or award A | +5,054 | – | 111,959 | Form 4 |
| 2026-09-16 | Fitzgerald MeghanDirector | Grant or award A | +5,054 | – | 41,162 | Form 4 |
| 2026-09-16 | Oren IlanDirector | Grant or award A | +5,054 | – | 123,680 | Form 4 |
| 2026-09-16 | Gold Daniel AllenDirector | Grant or award A | +5,054 | – | 8,965,815 | Form 4 |
| 2026-09-16 | Epperly Melissa B,Director | Grant or award A | +5,054 | – | 14,954 | Form 4 |
| 2026-09-10 | Gold Daniel AllenDirector | Shares withheld for tax F | −5,133 | 40.94 | 8,960,761 | Form 4 |
| 2026-09-10 | Momtazee James CDirector | Shares withheld for tax F | −2,905 | 40.94 | 106,905 | Form 4 |
| 2026-09-10 | Fitzgerald MeghanDirector | Shares withheld for tax F | −1,743 | 40.94 | 41,220 | Form 4 |
| 2026-09-10 | Oren IlanDirector | Shares withheld for tax F | −2,378 | 40.94 | 118,626 | Form 4 |
| 2026-09-10 | Epperly Melissa B,Director | Shares withheld for tax F | −2,179 | 40.94 | 14,838 | Form 4 |
| 2026-09-08 | Fitzgerald MeghanDirector | Option exercise M | +20,000 | 8.80 | 62,963 | Form 4 |
| 2026-08-28 | Venker EricPresident & Immunovant CEO | Option exercise M | +200,000 | 3.85 | 1,799,154 | Form 4 |
| 2026-08-21 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +144,756 | 3.85 | 18,775,495 | Form 4 |
| 2026-08-20 | Venker EricPresident & Immunovant CEO | Shares withheld for tax F | −13,909 | 36.84 | 1,599,154 | Form 4 |
| 2026-08-20 | Pulik RichardCFO | Shares withheld for tax F | −5,749 | 36.84 | 271,810 | Form 4 |
| 2026-08-20 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +17,519 | 3.85 | 18,648,258 | Form 4 |
| 2026-08-19 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +172,899 | 3.85 | 18,803,638 | Form 4 |
| 2026-08-18 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +105,141 | 3.85 | 18,735,880 | Form 4 |
| 2026-08-18 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +31,801 | 3.85 | 18,662,540 | Form 4 |
| 2026-08-17 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +284,707 | 3.85 | 18,915,446 | Form 4 |
| 2026-08-14 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +243,177 | 3.85 | 18,873,916 | Form 4 |
| 2026-07-27 | Venker EricPresident & Immunovant CEO | Option exercise M | +200,000 | 3.85 | 1,813,063 | Form 4 |
| 2026-07-17 | Oren IlanDirector | Grant or award A | +775 | – | 121,004 | Form 4 |
| 2026-07-17 | Epperly Melissa B,Director | Grant or award A | +543 | – | 17,017 | Form 4 |
| 2026-07-17 | Momtazee James CDirector | Grant or award A | +405 | – | 109,810 | Form 4 |
| 2026-06-30 | Fitzgerald MeghanDirector | Option exercise M | +10,000 | 8.80 | 52,963 | Form 4 |
| 2026-06-30 | Sukhatme MayukhDirector, President & CIO | Shares withheld for tax F | −46,878 | 35.39 | 18,630,739 | Form 4 |
| 2026-06-30 | Torti FrankPresident and Vant Chair | Shares withheld for tax F | −40,310 | 35.39 | 13,536,202 | Form 4 |
| 2026-06-30 | Gline MatthewDirector, CEO | Shares withheld for tax F | −76,171 | 35.39 | 16,659,945 | Form 4 |
| 2026-06-29 | Epperly Melissa B,Director | Option exercise M | +17,750 | 4.46 | 34,224 | Form 4 |
| 2026-06-26 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +500,000 | 3.85 | 19,177,617 | Form 4 |
| 2026-06-25 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +500,000 | 3.85 | 19,177,617 | Form 4 |
| 2026-06-24 | Venker EricPresident & Immunovant CEO | Option exercise M | +200,000 | 3.85 | 1,813,063 | Form 4 |
| 2026-06-20 | Humes JenniferChief Accounting Officer | Shares withheld for tax F | −3,582 | 31.43 | 109,782 | Form 4 |
| 2026-06-20 | Pulik RichardCFO | Shares withheld for tax F | −2,129 | 31.43 | 276,420 | Form 4 |
| 2026-05-22 | Venker EricPresident & Immunovant CEO | Option exercise M | +200,000 | 3.85 | 1,813,063 | Form 4 |
| 2026-05-20 | Pulik RichardCFO | Shares withheld for tax F | −18,962 | 32.41 | 278,549 | Form 4 |
| 2026-05-20 | Venker EricPresident & Immunovant CEO | Shares withheld for tax F | −34,483 | 32.41 | 1,613,063 | Form 4 |
| 2026-04-20 | Humes JenniferChief Accounting Officer | Grant or award A | +29,173 | – | 113,364 | Form 4 |
| 2026-04-20 | Pulik RichardCFO | Grant or award A | +60,644 | – | 297,511 | Form 4 |
| 2026-04-20 | Venker EricPresident & Immunovant CEO | Option exercise M | +200,000 | 3.85 | 1,847,546 | Form 4 |
| 2026-04-17 | Oren IlanDirector | Grant or award A | +896 | – | 120,324 | Form 4 |
| 2026-04-17 | Oren IlanDirector | Shares withheld for tax F | −95 | 29.83 | 120,229 | Form 4 |
| 2026-04-17 | Momtazee James CDirector | Grant or award A | +469 | – | 109,499 | Form 4 |
| 2026-04-17 | Momtazee James CDirector | Shares withheld for tax F | −94 | 29.83 | 109,405 | Form 4 |
| 2026-04-17 | Epperly Melissa B,Director | Grant or award A | +670 | – | 16,474 | Form 4 |
| 2026-03-31 | Torti FrankPresident and Vant Chair | Shares withheld for tax F | −160,035 | 27.70 | 13,576,512 | Form 4 |
| 2026-03-31 | Sukhatme MayukhDirector, President & CIO | Shares withheld for tax F | −187,512 | 27.70 | 18,677,617 | Form 4 |
| 2026-03-31 | Gline MatthewDirector, CEO | Shares withheld for tax F | −304,684 | 27.70 | 17,025,890 | Form 4 |
| 2026-03-30 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +58,391 | – | 18,894,938 | Form 4 |
| 2026-03-30 | Sukhatme MayukhDirector, President & CIO | Shares withheld for tax F | −29,809 | 26.41 | 18,865,129 | Form 4 |
| 2026-03-30 | Gline MatthewDirector, CEO | Option exercise M | +97,319 | – | 17,384,400 | Form 4 |
| 2026-03-30 | Gline MatthewDirector, CEO | Shares withheld for tax F | −53,826 | 26.41 | 17,330,574 | Form 4 |
| 2026-03-26 | Fitzgerald MeghanDirector | Option exercise M | +70,000 | 8.80 | 112,963 | Form 4 |
| 2026-03-20 | Humes JenniferChief Accounting Officer | Shares withheld for tax F | −14,526 | 27.70 | 97,729 | Form 4 |
| 2026-03-20 | Pulik RichardCFO | Shares withheld for tax F | −1,546 | 27.70 | 236,867 | Form 4 |
| 2026-03-17 | Venker EricPresident & Immunovant CEO | Option exercise M | +200,000 | 3.85 | 1,847,546 | Form 4 |
| 2026-02-23 | Torti FrankPresident and Vant Chair | Option exercise M | +587,390 | 3.85 | 14,323,937 | Form 4 |
| 2026-02-20 | Venker EricPresident & Immunovant CEO | Shares withheld for tax F | −7,051 | 27.15 | 1,647,546 | Form 4 |
| 2026-02-20 | Pulik RichardCFO | Shares withheld for tax F | −1,000 | 27.15 | 238,413 | Form 4 |
| 2026-02-20 | Torti FrankPresident and Vant Chair | Option exercise M | +1,012,610 | 3.85 | 14,749,157 | Form 4 |
| 2026-02-19 | Torti FrankPresident and Vant Chair | Option exercise M | +1,400,000 | 3.85 | 15,136,547 | Form 4 |
| 2026-02-13 | Venker EricPresident & Immunovant CEO | Option exercise M | +200,000 | 3.85 | 1,854,597 | Form 4 |
| 2026-02-09 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +651,558 | 12.68 | 19,488,105 | Form 4 |
| 2026-02-09 | Sukhatme MayukhDirector, President & CIO | Other J | −312,117 | 26.47 | 18,836,547 | Form 4 |
| 2026-01-20 | Epperly Melissa B,Director | Grant or award A | +815 | – | 57,719 | Form 4 |
| 2026-01-20 | Epperly Melissa B,Director | Shares withheld for tax F | −54 | 22.98 | 57,665 | Form 4 |
| 2026-01-20 | Oren IlanDirector | Grant or award A | +1,164 | – | 119,552 | Form 4 |
| 2026-01-20 | Oren IlanDirector | Shares withheld for tax F | −124 | 22.98 | 119,428 | Form 4 |
| 2026-01-20 | Momtazee James CDirector | Grant or award A | +609 | – | 109,152 | Form 4 |
| 2026-01-20 | Momtazee James CDirector | Shares withheld for tax F | −122 | 22.98 | 109,030 | Form 4 |
| 2026-01-12 | Venker EricPresident & Immunovant CEO | Option exercise M | +200,000 | 3.85 | 1,854,597 | Form 4 |
| 2025-12-31 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +2,449,877 | 12.68 | 21,286,424 | Form 4 |
| 2025-12-31 | Sukhatme MayukhDirector, President & CIO | Other J | −1,430,882 | 21.71 | 18,836,547 | Form 4 |
| 2025-12-29 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +748,358 | 12.68 | 19,584,905 | Form 4 |
| 2025-12-29 | Sukhatme MayukhDirector, President & CIO | Other J | −436,485 | 21.74 | 18,836,547 | Form 4 |
| 2025-12-24 | Venker EricPresident & Immunovant CEO | Option exercise M | +117,848 | 3.85 | 1,729,597 | Form 4 |
| 2025-12-24 | Torti FrankPresident and Vant Chair | Other J | −64,891 | 22.47 | 13,847,036 | Form 4 |
| 2025-12-24 | Torti FrankPresident and Vant Chair | Gift G | −110,489 | – | 13,736,547 | Form 4 |
| 2025-12-23 | Venker EricPresident & Immunovant CEO | Option exercise M | +313,841 | 3.85 | 1,811,749 | Form 4 |
| 2025-12-23 | Pulik RichardCFO | Option exercise M | +260,000 | 3.85 | 646,144 | Form 4 |
| 2025-12-23 | Torti FrankPresident and Vant Chair | Grant or award A | +175,380 | 22.45 | 13,911,927 | Form 4 |
| 2025-12-20 | Pulik RichardCFO | Shares withheld for tax F | −2,129 | 22.41 | 386,144 | Form 4 |
| 2025-12-17 | Sukhatme MayukhDirector, President & CIO | Option exercise M | +59,513 | 12.68 | 18,896,060 | Form 4 |
| 2025-12-17 | Sukhatme MayukhDirector, President & CIO | Other J | −32,682 | 23.09 | 18,836,547 | Form 4 |
| 2025-12-15 | Gline MatthewDirector, CEO | Option exercise M | +234,096 | 4.06 | 17,521,177 | Form 4 |
| 2025-12-15 | Gline MatthewDirector, CEO | Other J | −3,739 | 21.68 | 17,287,081 | Form 4 |
| 2025-12-15 | Gline MatthewDirector, CEO | Option exercise M | +1,363,711 | 12.68 | 18,650,792 | Form 4 |
| 2025-12-15 | Gline MatthewDirector, CEO | Other J | −797,595 | 21.68 | 17,287,081 | Form 4 |
| 2025-12-15 | Gline MatthewDirector, CEO | Option exercise M | +2,272,852 | 12.68 | 19,559,933 | Form 4 |
| 2025-12-15 | Gline MatthewDirector, CEO | Other J | −1,329,325 | 21.68 | 17,287,081 | Form 4 |
| 2025-12-15 | Ramaswamy Vivek10% owner | Option exercise M | +832,453 | 12.68 | 34,486,208 | Form 4 |
| 2025-12-15 | Ramaswamy Vivek10% owner | Other J | −478,708 | 22.05 | 33,653,755 | Form 4 |
| 2025-12-12 | Ramaswamy Vivek10% owner | Option exercise M | +4,672,724 | 12.68 | 38,326,479 | Form 4 |
| 2025-12-12 | Ramaswamy Vivek10% owner | Other J | −2,696,866 | 21.96 | 33,653,755 | Form 4 |
| 2025-12-11 | Ramaswamy Vivek10% owner | Option exercise M | +1,869,691 | 12.68 | 35,523,447 | Form 4 |
| 2025-12-11 | Ramaswamy Vivek10% owner | Other J | −1,095,550 | 21.64 | 33,653,755 | Form 4 |
| 2025-12-09 | Venker EricPresident & Immunovant CEO | Option exercise M | +200,000 | 3.85 | 1,697,908 | Form 4 |
| 2025-11-20 | Venker EricPresident & Immunovant CEO | Shares withheld for tax F | −7,051 | 20.27 | 1,497,908 | Form 4 |
| 2025-11-20 | Pulik RichardCFO | Shares withheld for tax F | −1,235 | 20.27 | 388,273 | Form 4 |
| 2025-11-07 | Venker EricPresident & Immunovant CEO | Option exercise M | +200,000 | 3.85 | 1,704,959 | Form 4 |
| 2025-10-20 | Oren IlanDirector | Grant or award A | +1,507 | – | 118,669 | Form 4 |
| 2025-10-20 | Oren IlanDirector | Shares withheld for tax F | −281 | 17.74 | 118,388 | Form 4 |
| 2025-10-20 | Momtazee James CDirector | Grant or award A | +789 | – | 108,701 | Form 4 |
| 2025-10-20 | Momtazee James CDirector | Shares withheld for tax F | −158 | 17.74 | 108,543 | Form 4 |
| 2025-10-20 | Epperly Melissa B,Director | Grant or award A | +1,056 | – | 56,904 | Form 4 |
| 2025-10-17 | Venker EricPresident & Immunovant CEO | Option exercise M | +118,418 | 15.85 | 1,623,377 | Form 4 |
| 2025-10-16 | Venker EricPresident & Immunovant CEO | Option exercise M | +318,282 | 15.85 | 1,823,241 | Form 4 |
| 2025-10-15 | Venker EricPresident & Immunovant CEO | Option exercise M | +414,683 | 15.85 | 1,919,642 | Form 4 |
| 2025-10-13 | Venker EricPresident & Immunovant CEO | Option exercise M | +20,727 | 15.85 | 1,525,686 | Form 4 |
| 2025-10-09 | Venker EricPresident & Immunovant CEO | Option exercise M | +104,940 | 15.85 | 1,609,899 | Form 4 |
| 2025-10-08 | Venker EricPresident & Immunovant CEO | Option exercise M | +10,307 | 15.85 | 1,515,266 | Form 4 |
| 2025-10-08 | Venker EricPresident & Immunovant CEO | Option exercise M | +128,295 | 7.45 | 1,643,561 | Form 4 |
| 2025-10-07 | Venker EricPresident & Immunovant CEO | Option exercise M | +67,171 | 15.85 | 1,572,130 | Form 4 |
| 2025-10-07 | Venker EricPresident & Immunovant CEO | Option exercise M | +107,131 | 7.45 | 1,679,261 | Form 4 |
| 2025-10-07 | Venker EricPresident & Immunovant CEO | Option exercise M | +180,859 | 3.85 | 1,860,120 | Form 4 |
| 2025-10-06 | Venker EricPresident & Immunovant CEO | Option exercise M | +127,355 | 15.85 | 1,632,314 | Form 4 |
| 2025-10-06 | Venker EricPresident & Immunovant CEO | Option exercise M | +24,900 | 7.45 | 1,657,214 | Form 4 |
| 2025-10-06 | Venker EricPresident & Immunovant CEO | Option exercise M | +19,141 | 3.85 | 1,676,355 | Form 4 |
| 2025-09-28 | Pulik RichardCFO | Shares withheld for tax F | −2,341 | 15.17 | 389,508 | Form 4 |
| 2025-09-22 | Venker EricPresident & Immunovant CEO | Option exercise M | +462,374 | 3.85 | 2,432,141 | Form 4 |
| 2025-09-22 | Venker EricPresident & Immunovant CEO | Option exercise M | +100,000 | 3.85 | 2,532,141 | Form 4 |
| 2025-09-20 | Pulik RichardCFO | Shares withheld for tax F | −2,129 | 15.04 | 391,849 | Form 4 |
| 2025-09-19 | Venker EricPresident & Immunovant CEO | Option exercise M | +1,000,000 | 3.85 | 2,653,585 | Form 4 |
| 2025-09-10 | Epperly Melissa B,Director | Grant or award A | +14,524 | – | 57,509 | Form 4 |
| 2025-09-10 | Epperly Melissa B,Director | Other J | −1,661 | 13.77 | 55,848 | Form 4 |
| 2025-09-10 | Momtazee James CDirector | Grant or award A | +14,524 | – | 111,194 | Form 4 |
| 2025-09-10 | Momtazee James CDirector | Other J | −3,282 | 13.77 | 107,912 | Form 4 |
| 2025-09-10 | Oren IlanDirector | Grant or award A | +14,524 | – | 119,205 | Form 4 |
| 2025-09-10 | Oren IlanDirector | Other J | −2,043 | 13.77 | 117,162 | Form 4 |
| 2025-09-10 | Fitzgerald MeghanDirector | Grant or award A | +14,524 | – | 43,900 | Form 4 |
| 2025-09-10 | Fitzgerald MeghanDirector | Other J | −937 | 13.77 | 42,963 | Form 4 |
| 2025-09-10 | Gold Daniel AllenDirector | Grant or award A | +14,524 | – | 8,971,164 | Form 4 |
| 2025-09-10 | Gold Daniel AllenDirector | Other J | −5,270 | 13.77 | 8,965,894 | Form 4 |
| 2025-09-10 | Manchester Keith SDirector | Grant or award A | +14,524 | – | 1,948,403 | Form 4 |
| 2025-08-28 | Pulik RichardCFO | Shares withheld for tax F | −2,340 | 11.94 | 393,978 | Form 4 |
| 2025-08-20 | Venker EricPresident & Immunovant CEO | Shares withheld for tax F | −7,051 | 11.72 | 1,653,585 | Form 4 |
| 2025-08-20 | Venker EricPresident & Immunovant CEO | Option exercise M | +100,000 | 3.85 | 1,753,585 | Form 4 |
| 2025-08-20 | Pulik RichardCFO | Shares withheld for tax F | −1,235 | 11.72 | 396,318 | Form 4 |
| 2025-07-30 | Venker EricPresident & Immunovant CEO | Grant or award A | +198,413 | – | 1,660,636 | Form 4 |
| 2025-07-30 | Torti FrankPresident and Vant Chair | Grant or award A | +1,836,547 | – | 1,836,547 | Form 4 |
| 2025-07-30 | Torti FrankPresident and Vant Chair | Grant or award A | +11,900,000 | – | 13,736,547 | Form 4 |
| 2025-07-28 | Pulik RichardCFO | Shares withheld for tax F | −1,919 | 11.35 | 397,553 | Form 4 |
| 2025-07-21 | Venker EricPresident & Immunovant CEO | Option exercise M | +100,000 | 3.85 | 1,562,223 | Form 4 |
| 2025-07-17 | Epperly Melissa B,Director | Grant or award A | +1,609 | – | 42,985 | Form 4 |
| 2025-07-17 | Momtazee James CDirector | Grant or award A | +1,201 | – | 96,911 | Form 4 |
| 2025-07-17 | Momtazee James CDirector | Shares withheld for tax F | −241 | 11.65 | 96,670 | Form 4 |
| 2025-06-28 | Pulik RichardCFO | Shares withheld for tax F | −1,653 | 11.39 | 399,472 | Form 4 |
| 2025-06-25 | Qvt Financial LPOther | Other J | −55,443 | – | 0 | Form 4 |
| 2025-06-25 | Qvt Financial LPOther | Other J | −6,205,368 | – | 8,441,428 | Form 4 |
| 2025-06-25 | Qvt Financial LPOther | Other J | −3,176,245 | – | 19,347,727 | Form 4 |
| 2025-06-25 | Qvt Financial LPOther | Other J | −19,311,790 | – | 0 | Form 4 |
| 2025-06-25 | Qvt Financial LPOther | Other J | −6,837,266 | – | 0 | Form 4 |
| 2025-06-25 | Qvt Financial LPOther | Other J | −1,170,646 | – | 1,592,480 | Form 4 |
| 2025-06-25 | Manchester Keith SDirector | Other J | −6,205,368 | – | 8,441,428 | Form 4 |
| 2025-06-25 | Manchester Keith SDirector | Other J | −3,176,245 | – | 19,347,727 | Form 4 |
| 2025-06-25 | Manchester Keith SDirector | Other J | −6,837,266 | – | 0 | Form 4 |
| 2025-06-25 | Manchester Keith SDirector | Other J | −1,170,646 | – | 1,592,480 | Form 4 |
| 2025-06-25 | Gold Daniel AllenDirector | Other J | −19,311,790 | – | 0 | Form 4 |
| 2025-06-25 | Gold Daniel AllenDirector | Other J | −6,837,266 | – | 0 | Form 4 |
| 2025-06-25 | Gold Daniel AllenDirector | Other J | −55,443 | – | 0 | Form 4 |
| 2025-06-25 | Gold Daniel AllenDirector | Other J | −1,170,646 | – | 1,592,480 | Form 4 |
| 2025-06-25 | Gold Daniel AllenDirector | Other J | −6,205,368 | – | 8,441,428 | Form 4 |
| 2025-06-25 | Gold Daniel AllenDirector | Other J | −3,176,245 | – | 19,347,727 | Form 4 |
| 2025-06-20 | Venker EricPresident & COO | Option exercise M | +100,000 | 3.85 | 1,562,223 | Form 4 |
| 2025-06-20 | Pulik RichardCFO | Shares withheld for tax F | −1,503 | 11.45 | 399,056 | Form 4 |
| 2025-06-03 | Venker EricPresident & COO | Option exercise M | +785,026 | 3.85 | 2,028,501 | Form 4 |
| 2025-06-02 | Venker EricPresident & COO | Option exercise M | +600,000 | 3.85 | 1,677,197 | Form 4 |
| 2025-05-28 | Pulik RichardCFO | Shares withheld for tax F | −1,653 | 10.62 | 400,559 | Form 4 |
| 2025-05-20 | Gline MatthewDirector, CEO | Shares withheld for tax F | −10,945 | 11.04 | 17,283,766 | Form 4 |
| 2025-05-20 | Venker EricPresident & COO | Shares withheld for tax F | −39,148 | 11.04 | 1,077,197 | Form 4 |
| 2025-05-20 | Venker EricPresident & COO | Option exercise M | +100,000 | 3.85 | 1,177,197 | Form 4 |
| 2025-05-20 | Pulik RichardCFO | Shares withheld for tax F | −3,487 | 11.04 | 402,212 | Form 4 |
| 2025-04-28 | Pulik RichardCFO | Shares withheld for tax F | −1,653 | 11.19 | 405,699 | Form 4 |
| 2025-04-21 | Pulik RichardCFO | Grant or award A | +141,464 | – | 407,352 | Form 4 |
| 2025-04-21 | Venker EricPresident & COO | Option exercise M | +100,000 | 3.85 | 1,216,345 | Form 4 |
| 2025-04-20 | Gline MatthewDirector, CEO | Shares withheld for tax F | −10,945 | 10.15 | 17,294,711 | Form 4 |
| 2025-04-20 | Venker EricPresident & COO | Shares withheld for tax F | −10,945 | 10.15 | 1,116,345 | Form 4 |
| 2025-04-17 | Oren IlanDirector | Grant or award A | +2,296 | – | 104,796 | Form 4 |
| 2025-04-17 | Oren IlanDirector | Shares withheld for tax F | −115 | 11.65 | 104,681 | Form 4 |
| 2025-04-17 | Oren IlanDirector | Grant or award A | +2,635 | – | 102,564 | Form 4 |
| 2025-04-17 | Oren IlanDirector | Shares withheld for tax F | −64 | 10.15 | 102,500 | Form 4 |
| 2025-04-17 | Momtazee James CDirector | Grant or award A | +1,379 | – | 95,986 | Form 4 |
| 2025-04-17 | Momtazee James CDirector | Shares withheld for tax F | −276 | 10.15 | 95,710 | Form 4 |
| 2025-04-17 | Epperly Melissa B,Director | Grant or award A | +1,847 | – | 41,376 | Form 4 |
| 2025-03-28 | Pulik RichardCFO | Shares withheld for tax F | −1,653 | 10.38 | 265,888 | Form 4 |
| 2025-03-24 | Venker EricPresident & COO | Option exercise M | +602,311 | 3.85 | 1,561,768 | Form 4 |
| 2025-03-20 | Gline MatthewDirector, CEO | Shares withheld for tax F | −10,945 | 10.97 | 17,305,656 | Form 4 |
| 2025-03-20 | Pulik RichardCFO | Shares withheld for tax F | −1,504 | 10.97 | 267,541 | Form 4 |
| 2025-03-20 | Humes JenniferChief Accounting Officer | Grant or award A | +112,255 | – | 112,255 | Form 4 |
| 2025-03-20 | Venker EricPresident & COO | Shares withheld for tax F | −10,945 | 10.97 | 874,979 | Form 4 |
| 2025-03-20 | Venker EricPresident & COO | Option exercise M | +400,000 | 3.85 | 1,274,979 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.